{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T23:26:27Z","timestamp":1789255587905,"version":"build-2803163510"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Rheumatol"],"DOI":"10.1186\/s41927-025-00516-9","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T04:32:29Z","timestamp":1748233949000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Personalized dose reduction strategies for biologic disease-modifying antirheumatic drugs for treating axial spondyloarthritis: a clinical and economic evaluation with predictive modeling"],"prefix":"10.1186","volume":"9","author":[{"given":"Bui Hai","family":"Binh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nguyen Thi Thu","family":"Phuong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vu Thi Thanh","family":"Hang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ngo Thi Thuc","family":"Nhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nguyen Thi Nhu","family":"Hoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoang","family":"Van Dung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"issue":"7568","key":"516_CR1","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1136\/bmj.38954.689583.DE","volume":"333","author":"CM McVeigh","year":"2006","unstructured":"McVeigh CM, Cairns AP. Diagnosis and management of ankylosing spondylitis. BMJ (Clinical Res ed). 2006;333(7568):581\u20135.","journal-title":"BMJ (Clinical Res ed)"},{"issue":"4","key":"516_CR2","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1093\/rheumatology\/ket387","volume":"53","author":"LE Dean","year":"2014","unstructured":"Dean LE, Jones GT, MacDonald AG, Downham C, Sturrock RD, Macfarlane GJ. Global prevalence of ankylosing spondylitis. Rheumatology (Oxford). 2014;53(4):650\u20137.","journal-title":"Rheumatology (Oxford)"},{"issue":"7809","key":"516_CR3","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/S0140-6736(73)91360-3","volume":"1","author":"DA Brewerton","year":"1973","unstructured":"Brewerton DA, Hart FD, Nicholls A, Caffrey M, James DC, Sturrock RD. Ankylosing spondylitis and HL-A 27. Lancet. 1973;1(7809):904\u20137.","journal-title":"Lancet"},{"key":"516_CR4","doi-asserted-by":"publisher","first-page":"603726","DOI":"10.3389\/fimmu.2021.603726","volume":"12","author":"BP Wordsworth","year":"2021","unstructured":"Wordsworth BP, Cohen CJ, Davidson C, Vecellio M. Perspectives on the genetic associations of ankylosing spondylitis. Front Immunol. 2021;12:603726.","journal-title":"Front Immunol"},{"key":"516_CR5","first-page":"4","volume":"78","author":"A Boonen","year":"2006","unstructured":"Boonen A, van der Linden SM. The burden of ankylosing spondylitis. J Rheumatol Suppl. 2006;78:4\u201311.","journal-title":"J Rheumatol Suppl"},{"issue":"7","key":"516_CR6","doi-asserted-by":"publisher","first-page":"A376","DOI":"10.1016\/j.jval.2014.08.2593","volume":"17","author":"R Hegyi","year":"2014","unstructured":"Hegyi R, Nagy B, Koncz A, Huybrechts I, Lavicky J, Ferenczik A. Burden of disease analysis of ankylosing spondylitis in Hungary. Value Health. 2014;17(7):A376\u20137.","journal-title":"Value Health"},{"issue":"3","key":"516_CR7","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/j.1524-4733.2007.00252.x","volume":"11","author":"G Kobelt","year":"2008","unstructured":"Kobelt G, Sobocki P, Mulero J, Gratacos J, Pocovi A, Collantes-Estevez E. The burden of ankylosing spondylitis in Spain. Value Health. 2008;11(3):408\u201315.","journal-title":"Value Health"},{"issue":"1","key":"516_CR8","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1136\/ard-2022-223298","volume":"82","author":"C Webers","year":"2023","unstructured":"Webers C, Ortolan A, Sepriano A, Falzon L, Baraliakos X, Landewe RBM, et al. Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis. Ann Rheum Dis. 2023;82(1):130\u201341.","journal-title":"Ann Rheum Dis"},{"issue":"Supplement6","key":"516_CR9","doi-asserted-by":"publisher","first-page":"vi29","DOI":"10.1093\/rheumatology\/keab523","volume":"60","author":"K Klavdianou","year":"2021","unstructured":"Klavdianou K, Tsiami S, Baraliakos X. New developments in ankylosing spondylitis\u2014status in 2021. Rheumatology. 2021;60(Supplement6):vi29\u201337.","journal-title":"Rheumatology"},{"issue":"4","key":"516_CR10","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1080\/14728214.2018.1547706","volume":"23","author":"WM Oo","year":"2018","unstructured":"Oo WM, Yu SP, Daniel MS, Hunter DJ. Disease-modifying drugs in osteoarthritis: current Understanding and future therapeutics. Expert Opin Emerg Drugs. 2018;23(4):331\u201347.","journal-title":"Expert Opin Emerg Drugs"},{"issue":"24","key":"516_CR11","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1001\/jama.2018.19319","volume":"320","author":"D Gregori","year":"2018","unstructured":"Gregori D, Giacovelli G, Minto C, Barbetta B, Gualtieri F, Azzolina D, et al. Association of Pharmacological treatments with Long-term pain control in patients with knee osteoarthritis: A systematic review and Meta-analysis. JAMA. 2018;320(24):2564\u201379.","journal-title":"JAMA"},{"issue":"4 Suppl 55","key":"516_CR12","first-page":"S118","volume":"27","author":"LC Franke","year":"2009","unstructured":"Franke LC, Ament AJ, van de Laar MA, Boonen A, Severens JL. Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol. 2009;27(4 Suppl 55):S118\u201323.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"516_CR13","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3899\/jrheum.150540","volume":"43","author":"JD Greenberg","year":"2016","unstructured":"Greenberg JD, Palmer JB, Li Y, Herrera V, Tsang Y, Liao M. Healthcare resource use and direct costs in patients with ankylosing spondylitis and psoriatic arthritis in a large US cohort. J Rheumatol. 2016;43(1):88\u201396.","journal-title":"J Rheumatol"},{"issue":"1","key":"516_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40744-017-0055-5","volume":"4","author":"LM Verhoef","year":"2017","unstructured":"Verhoef LM, Tweehuysen L, Hulscher ME, Fautrel B, den Broeder AA. bDMARD dose reduction in rheumatoid arthritis: A narrative review with systematic literature search. Rheumatol Ther. 2017;4(1):1\u201324.","journal-title":"Rheumatol Ther"},{"key":"516_CR15","unstructured":"Mei J, Feifeng R, Yaning Z, Ru-yu Y, Wenhan H, Xia N. Efficacy and safety of down-titration versus continuation strategies O F biological disease-modifying anti-rheumatic drugs in patients with R heumatoid arthritis with low disease activity or in remission: a syste matic review and meta-analysis. Clin Exp Rheumatol. 2017;35(1):152\u201360."},{"issue":"2","key":"516_CR16","first-page":"174","volume":"33","author":"S Arends","year":"2015","unstructured":"Arends S, van der Veer E, Kamps FB, Houtman PM, Bos R, Bootsma H, et al. Patient-tailored dose reduction of TNF-\u03b1 blocking agents in ankylosing spondylitis patients with stable low disease activity in daily clinical practice. Clin Exp Rheumatol. 2015;33(2):174\u201380.","journal-title":"Clin Exp Rheumatol"},{"issue":"10","key":"516_CR17","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1093\/rheumatology\/kew269","volume":"55","author":"W Fong","year":"2016","unstructured":"Fong W, Holroyd C, Davidson B, Armstrong R, Harvey N, Dennison E, et al. The effectiveness of a real life dose reduction strategy for tumour Ne Crosis factor inhibitors in ankylosing spondylitis and psoriatic arthr Itis. Rheumatology. 2016;55(10):1837\u201342.","journal-title":"Rheumatology"},{"issue":"2","key":"516_CR18","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1080\/03009742.2022.2028364","volume":"52","author":"J Ruwaard","year":"2023","unstructured":"Ruwaard J, MJ LA, Kneepkens EL, Krieckaert C, Nurmohamed MT, Hooijberg F, et al. Interval prolongation of etanercept in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a randomized controlled trial. Scand J Rheumatol. 2023;52(2):129\u201336.","journal-title":"Scand J Rheumatol"},{"issue":"11","key":"516_CR19","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1080\/17512433.2016.1234374","volume":"9","author":"F Atzeni","year":"2016","unstructured":"Atzeni F, Benucci M, Talotta R, Masala IF, Sarzi-Puttini P, Govoni M. What are the dangers of biological therapy discontinuation or dose reduction strategies when treating rheumatoid arthritis? Expert Rev Clin Pharmacol. 2016;9(11):1403\u201311.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"2","key":"516_CR20","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1093\/mr\/roac038","volume":"33","author":"M Kuwana","year":"2022","unstructured":"Kuwana M, Tamura N, Yasuda S, Fujio K, Shoji A, Yamaguchi H, et al. Cost-effectiveness analyses of biologic and targeted synthetic disease -modifying anti-rheumatic diseases in patients with rheumatoid arthrit is: three approaches with a cohort simulation and real-world data. Mod Rheumatol. 2022;33(2):302\u201311.","journal-title":"Mod Rheumatol"},{"issue":"4","key":"516_CR21","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S van der Linden","year":"1984","unstructured":"van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the new York criteria. Arthritis Rheum. 1984;27(4):361\u20138.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"516_CR22","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde D, Ramiro S, Landew\u00e9 R, Baraliakos X, Van den Bosch F, Sepriano A, et al. 2016 Update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978\u201391.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"516_CR23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/ard-2022-223296","volume":"82","author":"S Ramiro","year":"2023","unstructured":"Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023;82(1):19\u201334.","journal-title":"Ann Rheum Dis"},{"key":"516_CR24","unstructured":"Gold MRSJ, Russell LB, Weinstein MC, editors. Cost-Effectiveness in health and medicine. ed. n, editor. Oxford University Press; 2016."},{"issue":"3","key":"516_CR25","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1093\/rheumatology\/24.3.242","volume":"24","author":"HS Goie The","year":"1985","unstructured":"Goie The HS, Steven MM, van der Linden SM, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a comparison of the Rome, new York and modified new York criteria in patients with a positive clinical history screening test for ankylosing spondylitis. Br J Rheumatol. 1985;24(3):242\u20139.","journal-title":"Br J Rheumatol"},{"issue":"12","key":"516_CR26","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1136\/ard.2008.100826","volume":"68","author":"D van der Heijde","year":"2009","unstructured":"van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68(12):1811\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"516_CR27","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index. J Rhuematol. 1994;21(12):2286\u201391.","journal-title":"J Rhuematol"},{"issue":"1","key":"516_CR28","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1136\/ard.2008.094870","volume":"68","author":"C Lukas","year":"2009","unstructured":"Lukas C, Landewe R, Sieper J, Dougados M, Davis J, Braun J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68(1):18\u201324.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"516_CR29","first-page":"592","volume":"34","author":"JW Park","year":"2016","unstructured":"Park JW, Yoon YI, Lee JH, Park JK, Lee EB, Song YW, et al. Low dose etanercept treatment for maintenance of clinical remission in ankylosing spondylitis. Clin Exp Rheumatol. 2016;34(4):592\u20139.","journal-title":"Clin Exp Rheumatol"},{"key":"516_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/289845","volume":"2013","author":"B M\u00f6rck","year":"2013","unstructured":"M\u00f6rck B, Pullerits R, Geijer M, Bremell T, Forsblad-d\u2019Elia H. Infliximab dose reduction sustains the clinical treatment effect in ac Tive HLAB27 positive ankylosing spondylitis: A Two-Year pilot study. Mediat Inflamm. 2013;2013:1\u20139.","journal-title":"Mediat Inflamm"},{"key":"516_CR31","doi-asserted-by":"crossref","unstructured":"Norlin JM, L\u00f6fvendahl S, Schmitt-Egenolf M. The influence of socioeconomic factors on access to biologics in psoriasis. J Clin Med. 2023;12(23).","DOI":"10.3390\/jcm12237234"},{"issue":"11","key":"516_CR32","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1136\/annrheumdis-2013-203819","volume":"73","author":"P Putrik","year":"2014","unstructured":"Putrik P, Ramiro S, Kvien TK, Sokka T, Uhlig T, Boonen A. Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country\u2019s wealth? Ann Rheum Dis. 2014;73(11):2010\u201321.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"516_CR33","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s11926-024-01137-w","volume":"26","author":"H Chaudhary","year":"2024","unstructured":"Chaudhary H, Bittar M, Daoud A, Magrey M. Dose tapering and discontinuation of biologic DMARDs in axial spondylo arthritis: A narrative review (2023 SPARTAN annual meeting Proceedings). Curr Rheumatol Rep. 2024;26(5):155\u201363.","journal-title":"Curr Rheumatol Rep"},{"issue":"1","key":"516_CR34","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/msc.1367","volume":"17","author":"S Hewlett","year":"2018","unstructured":"Hewlett S, Haig-Ferguson A, Rose\u2010Parfitt E, Halls S, Freke S, Creamer P. Dose reduction of biologic therapy in inflammatory arthritis: A qualit ative study of patients\u2019 perceptions and needs. Musculoskelet Care. 2018;17(1):63\u201371.","journal-title":"Musculoskelet Care"},{"issue":"5","key":"516_CR35","first-page":"884","volume":"36","author":"F Lian","year":"2018","unstructured":"Lian F, Zhou J, Wang Y, Chen D, Xu H, Liang L. Efficiency of dose reduction strategy of etanercept in patients with axial spondyloarthritis. Clin Exp Rheumatol. 2018;36(5):884\u201390.","journal-title":"Clin Exp Rheumatol"},{"issue":"8","key":"516_CR36","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s40273-018-0675-9","volume":"36","author":"P Emery","year":"2018","unstructured":"Emery P, Van Keep M, Beard S, Graham C, Miles L, Jugl SM, et al. Cost effectiveness of Secukinumab for the treatment of active ankylosi Ng spondylitis in the UK. PharmacoEconomics. 2018;36(8):1015\u201327.","journal-title":"PharmacoEconomics"},{"issue":"8","key":"516_CR37","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1093\/rheumatology\/kem031","volume":"46","author":"MF Botteman","year":"2007","unstructured":"Botteman MF, Hay JW, Luo MP, Curry AS, Wong RL, van Hout BA. Cost effectiveness of adalimumab for the treatment of ankylosing spond Ylitis in the united Kingdom. Rheumatology. 2007;46(8):1320\u20138.","journal-title":"Rheumatology"},{"issue":"2","key":"516_CR38","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1136\/ard.2008.103887","volume":"69","author":"B Fautrel","year":"2010","unstructured":"Fautrel B, Benhamou M, Breban M, Roy C, Lenoir C, Trape G, et al. Cost effectiveness of two therapeutic regimens of Infliximab in Ankylo Sing spondylitis: economic evaluation within a randomised controlled t Rial. Ann Rheum Dis. 2010;69(2):424\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"516_CR39","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s40273-014-0165-7","volume":"32","author":"A Diamantopoulos","year":"2014","unstructured":"Diamantopoulos A, Finckh A, Huizinga T, Sungher DK, Sawyer L, Neto D, et al. Tocilizumab in the treatment of rheumatoid arthritis: A Cost-Effective Ness analysis in the UK. PharmacoEconomics. 2014;32(8):775\u201387.","journal-title":"PharmacoEconomics"},{"issue":"11","key":"516_CR40","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1136\/annrheumdis-2015-208317","volume":"75","author":"W Kievit","year":"2016","unstructured":"Kievit W, van Herwaarden N, van den Hoogen FHJ, van Vollenhoven RF, Bijlsma JWJ, van den Bemt BJF, et al. Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Ann Rheum Dis. 2016;75(11):1939\u201344.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"516_CR41","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s10198-019-01110-w","volume":"21","author":"A Svedbom","year":"2020","unstructured":"Svedbom A, Dal\u00e9n J, Iverg\u00e5rd M, Borse RH, Black CM, Luttropp K, et al. The value of persistence in treatment with subcutaneous TNF-alpha inhibitors for ankylosing spondylitis. Eur J Health Economics: HEPAC: Health Econ Prev Care. 2020;21(1):45\u201354.","journal-title":"Eur J Health Economics: HEPAC: Health Econ Prev Care"},{"issue":"3","key":"516_CR42","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s40744-021-00345-5","volume":"8","author":"C G\u00f3mez-Arango","year":"2021","unstructured":"G\u00f3mez-Arango C, Gorostiza I, \u00dacar E, Garc\u00eda-Vivar ML, P\u00e9rez CE, De Dios JR, et al. Cost-Effectiveness of therapeutic drug Monitoring-Guided adalimumab Th erapy in rheumatic diseases: A prospective, pragmatic trial. Rheumatol Ther. 2021;8(3):1323\u201339.","journal-title":"Rheumatol Ther"},{"issue":"6","key":"516_CR43","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1136\/ard.2010.147744","volume":"70","author":"N Vastesaeger","year":"2011","unstructured":"Vastesaeger N, van der Heijde D, Inman RD, Wang Y, Deodhar A, Hsu B, et al. Predicting the outcome of ankylosing spondylitis therapy. Ann Rheum Dis. 2011;70(6):973\u201381.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"516_CR44","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s10067-019-04553-x","volume":"39","author":"A Deodhar","year":"2020","unstructured":"Deodhar A, Rozycki M, Garges C, Shukla O, Arndt T, Grabowsky T, et al. Use of machine learning techniques in the development and refinement of a predictive model for early diagnosis of ankylosing spondylitis. Clin Rheumatol. 2020;39(4):975\u201382.","journal-title":"Clin Rheumatol"},{"issue":"3","key":"516_CR45","doi-asserted-by":"publisher","first-page":"e0279076","DOI":"10.1371\/journal.pone.0279076","volume":"18","author":"J Kennedy","year":"2023","unstructured":"Kennedy J, Kennedy N, Cooksey R, Choy E, Siebert S, Rahman M, et al. Predicting a diagnosis of ankylosing spondylitis using primary care health records-A machine learning approach. PLoS ONE. 2023;18(3):e0279076.","journal-title":"PLoS ONE"},{"key":"516_CR46","doi-asserted-by":"crossref","unstructured":"Seulkee L, Hyungjin YE, H K, Jaejoon CEK. L. Machine learning to predict early TNF inhibitor users in patients with ankylosing spondylitis. Sci Rep. 2020;10(1):20299.","DOI":"10.1038\/s41598-020-75352-7"},{"issue":"3","key":"516_CR47","doi-asserted-by":"publisher","first-page":"e222312","DOI":"10.1001\/jamanetworkopen.2022.2312","volume":"5","author":"R Wang","year":"2022","unstructured":"Wang R, Dasgupta A, Ward MM. Predicting probability of response to tumor necrosis factor inhibitors for individual patients with ankylosing spondylitis. JAMA Netw Open. 2022;5(3):e222312.","journal-title":"JAMA Netw Open"},{"key":"516_CR48","doi-asserted-by":"crossref","unstructured":"Juyeon K, Tae-Han L, S P, Seunghun L, Tae-Hwan BK. K. Prediction of radiographic progression pattern in patients with Ankylo Sing spondylitis using group-based trajectory modeling and decision tr Ees. Front Med. 2022;9:994308.","DOI":"10.3389\/fmed.2022.994308"}],"container-title":["BMC Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-025-00516-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41927-025-00516-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-025-00516-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T06:01:53Z","timestamp":1748239313000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcrheumatol.biomedcentral.com\/articles\/10.1186\/s41927-025-00516-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,26]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["516"],"URL":"https:\/\/doi.org\/10.1186\/s41927-025-00516-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5917710\/v1","asserted-by":"object"}]},"ISSN":["2520-1026"],"issn-type":[{"value":"2520-1026","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,26]]},"assertion":[{"value":"28 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was reviewed and approved by the Institutional Review Board of Hai Phong International Hospital, approval number of 160520\/Q\u0110-\u0110KQT. All methods were carried out in accordance with relevant guidelines and regulations. Written informed consent was obtained from all individual participants included in the study. The study was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"60"}}